New, High-Impact Studies to Be Featured at World’s Largest Clinical Cancer Research Meeting

For immediate release
April 25, 2018
Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

ALEXANDRIA, Va. – The latest in clinical cancer research, from new treatment options and advances in precision medicine to insights for improving access to care, will be highlighted in the official Press Program for the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO).

The 2018 ASCO Annual Meeting, taking place June 1-5 in Chicago, will bring together more than 32,000 oncology professionals from around the world. The theme of this year’s conference is Delivering Discoveries: Expanding the Reach of Precision Medicine.

More than 2,500 abstracts were accepted for presentation on site at the Annual Meeting, and an additional 3,350 abstracts were accepted for online publication. The vast majority of these abstracts will be publicly posted on abstracts.asco.org on Wednesday, May 16, at 5:00 p.m. ET. An embargoed presscast for media will be held earlier that day to highlight six significant abstracts from this group. Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released on site throughout the Annual Meeting and highlighted in daily press briefings.

EMBARGOED PRESSCAST – Wednesday, May 16, 12:00 noon ET
Embargo will lift on May 16 at 5:00 p.m. ET for the following studies presented in this virtual
presscast:

- A randomized, phase III trial comparing 6 versus 12 months of adjuvant targeted therapy trastuzumab for patients with HER2-positive early breast cancer (Abstract 506)

- A study exploring the use of mobile and sensor technology to monitor symptoms in patients with head and neck cancer receiving radiation therapy (Abstract 6063)

- An analysis of lung cancer screening rates following the 2013 United States Preventive Services Task Force screening recommendations (Abstract 6504)

- A study comparing the time to receive results and total cost of next-generation sequencing versus sequential single-gene tumor testing for patients with advanced non-small cell lung cancer (Abstract 9031)

- A randomized trial investigating acupuncture and cognitive behavioral therapy for the treatment of insomnia in cancer survivors (Abstract 10001)

- A randomized, phase III trial adding methotrexate and nelarabine to intensive chemotherapy for T-cell malignancies in children and young adults (Abstract 10500)

RESEARCH TO BE RELEASED ON SITE AT THE ANNUAL MEETING

News of the Day: Friday, June 1, 1:00-2:00 p.m. CT

Embargo will lift at 1:00 p.m. CT for studies presented in this briefing:

- A study comparing chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Washington state versus British Columbia, Canada (Abstract LBA3579)

- An analysis of overall survival for black and white men in the U.S. with metastatic prostate cancer treated with chemotherapy on clinical trials (Abstract LBA5005)

- A prospective study comparing metastatic prostate cancer response to hormone treatment in black vs. white men in the U.S. (Abstract LBA5009)

- A study analyzing likelihood of receiving intensive treatment for head and neck cancer in women versus men (Abstract LBA6002)

- A randomized trial exploring whether geriatric assessment improves communication with older patients with cancer (Abstract LBA10003)

News of the Day: Saturday, June 2, 8:00-9:00 a.m. CT
Embargo will lift at 6:30 a.m. CT for studies presented in this briefing:

- A randomized, phase III trial investigating a novel therapy targeting PI3K, taselisib, with hormone therapy, for the treatment of advanced breast cancer (Abstract LBA1006)

- A study analyzing whether microsatellite instability is predictive for Lynch Syndrome across cancer types (Abstract LBA1509)

- An analysis of long-term survival for patients with cancer based on the molecular pathway targeted with treatment (Abstract LBA2553)

- A study assessing the possibility of using a blood test to detect early-stage lung cancer (Abstract LBA8501)

- A randomized, phase III trial evaluating the addition of the immunotherapy atezolizumab to chemotherapy as first-line treatment for patients with advanced, squamous non-small cell lung cancer (Abstract LBA9000)

**News of the Day: Sunday, June 3, 8:00-9:00 a.m. CT**

Embargo will lift at 6:30 a.m. CT for studies presented in this briefing:

- A randomized, phase III trial exploring chemotherapy and hormone therapy compared to hormone therapy alone for women with breast cancer who have an intermediate risk of recurrence based on a genomic test (Abstract LBA1, Plenary)

- A randomized, phase III trial adding low-dose maintenance chemotherapy after standard treatment for children with high-risk rhabdomyosarcoma, a rare cancer of the muscle tissue (Abstract LBA2, Plenary)

- A randomized, phase III trial examining the need for surgical removal of the kidney (nephrectomy) in patients with metastatic kidney cancer (Abstract LBA3, Plenary)

- A randomized, phase III trial studying the immunotherapy pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer that expresses lower levels of PD-L1 (Abstract LBA4, Plenary)

**News of the Day: Monday, June 4, 8:00-9:00 a.m. CT**

Embargo will lift at 6:30 a.m. CT for studies presented in this briefing:

- A randomized, phase III trial of hyperthermic intra-peritoneal chemotherapy given after surgery to patients with colorectal peritoneal carcinomatosis from colorectal cancer (Abstract LBA3503)
• A randomized, phase III trial investigating a combined chemotherapy treatment (mFOLFIRINOX) versus standard gemcitabine after pancreatic cancer surgery (Abstract LBA4001)

• A randomized, phase III trial evaluating the benefit of chemotherapy and radiation prior to surgery for patients with pancreatic cancer (Abstract LBA4002)

• A randomized, phase III trial studying antacid and aspirin for the prevention of esophageal cancer (Abstract LBA4008)

MEDIA RESOURCES

**Media registration:** To participate in the embargoed May 16 presscast and/or register to attend the ASCO Annual Meeting in Chicago, please visit ASCO's Media Headquarters at mediahq.asco.org. Step-by-step instructions are available online.

Media Headquarters submission must be completed no later than Friday, May 11, to participate in the May 16 presscast. Pre-registration is required for on-site attendance and must be completed by Friday, May 18.

**Annual Meeting Media Resource Center:** Visit asco.org/AMMRC for press releases, the press briefing schedule, embargo policies, high-resolution photos, and the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations).

**Cancer.Net:** ASCO’s website for oncologist-approved cancer information

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and
follow us on Facebook, Twitter, LinkedIn, and YouTube.